Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

A study of biologic-naive patients with psoriasis or PsA found that IL-17, IL-12/23, and IL-23 inhibitors have comparable cardiovascular and thrombotic risk profiles as TNF inhibitors.

Calcipotriol-plus–5-FU therapy activates immune pathways, offering long-lasting protection against squamous cell carcinoma by ...